Almac

Executive Summary

Almac Group is a leading global contract development and manufacturing organization (CDMO) headquartered in Craigavon, United Kingdom. Founded in 2002, the company provides integrated services across the entire drug development lifecycle, including drug discovery, diagnostic services, small molecule manufacturing, and commercial distribution. With 501-1000 employees, Almac partners with pharmaceutical and biotechnology clients to accelerate development and commercialization of therapies. As a private, pre-clinical stage company, Almac's revenue is derived from fee-for-service contracts rather than product sales, positioning it as a key enabler in the pharmaceutical supply chain. The CDMO market is experiencing robust growth driven by increasing drug development outsourcing and demand for specialized manufacturing capabilities. Almac's comprehensive service offerings and established track record in the UK and globally support its competitive position. Key catalysts for Almac include expansion of its manufacturing capacity to address growing demand, particularly in sterile injectables and high-potency drugs; strategic partnerships with emerging biotech firms to secure long-term supply agreements; and potential investment in new technologies such as continuous manufacturing or advanced analytics to enhance efficiency and service differentiation. These factors are expected to drive revenue growth and potentially increase Almac's market share in the fragmented CDMO landscape.

Upcoming Catalysts (preview)

• Q3 2026Completion of Capacity Expansion at Craigavon Facility85% success
• TBDSecuring Multi-Year Strategic Partnership with Top-30 Pharma60% success
• Q1 2027Investment in Continuous Manufacturing Technology Platform70% success